Gilead’s Twice-Yearly Shot Shows 100% Efficacy in Phase III HIV Prevention Tr...
Pictured: Signage outside Gilead's headquarters in California/iStock, Sundry Photography Gilead Sciences’ antiviral demonstrated 100% efficacy for HIV prevention in cisgender women in Phase III trial results announced Thursday. The twice-yearly …